Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia | Zendy

Matthew A. Lunning | Zendy; Julie M. Vose | Zendy; Loretta J. Nastoupil | Zendy; Nathan Fowler | Zendy; Jan A. Burger | Zendy; William G. Wierda | Zendy; Marshall T. Schreeder | Zendy; Tanya Siddiqi | Zendy; Christopher R. Flowers | Zendy; Jonathon B. Cohen | Zendy; Peter Sportelli | Zendy; Hari P. Miskin | Zendy; Michael Weiss | Zendy; Susan O’Brien | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Author(s) -

Matthew A. Lunning,

Julie M. Vose,

Loretta J. Nastoupil,

Nathan Fowler,

Jan A. Burger,

William G. Wierda,

Marshall T. Schreeder,

Tanya Siddiqi,

Christopher R. Flowers,

Jonathon B. Cohen,

Peter Sportelli,

Hari P. Miskin,

Michael Weiss,

Susan O’Brien

Publication year - 2019

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood.2019002118

Subject(s) - chronic lymphocytic leukemia , medicine , lymphoma , immune system , toxicity , diarrhea , refractory (planetary science) , leukemia , immunology , cancer research , oncology , gastroenterology , biology , astrobiology

Key Points U2 exhibited low rates of immune-mediated toxicities associated with other PI3K-δ, including diarrhea, colitis, pneumonia, and hepatic toxicity. This combination had promising preliminary activity across a broad range of B-cell malignancies, including a 17% complete response rate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research